Sisram Medical Ltd (HKG:1696)
4.250
0.00 (0.00%)
At close: Jan 21, 2026
Sisram Medical Revenue
Sisram Medical had revenue of $165.48M USD in the half year ending June 30, 2025, a decrease of -3.58%. This brings the company's revenue in the last twelve months to $345.86M, down -2.96% year-over-year. In the year 2024, Sisram Medical had annual revenue of $349.11M, down -2.83%.
Revenue (ttm)
$345.86M
Revenue Growth
-2.96%
P/S Ratio
0.73
Revenue / Employee
$340.75K
Employees
1,015
Market Cap
1.99B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 349.11M | -10.18M | -2.83% |
| Dec 31, 2023 | 359.29M | 4.81M | 1.36% |
| Dec 31, 2022 | 354.48M | 60.19M | 20.45% |
| Dec 31, 2021 | 294.29M | 132.20M | 81.56% |
| Dec 31, 2020 | 162.10M | -11.43M | -6.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Gaush Meditech | 1.58B |
| AK Medical Holdings | 1.52B |
| Peijia Medical | 731.61M |
| Acotec Scientific Holdings | 649.64M |
| LEPU ScienTech Medical Technology (Shanghai) | 605.14M |
| MicroTech Medical (Hangzhou) | 482.95M |
| Venus Medtech (Hangzhou) | 468.17M |
| Shanghai HeartCare Medical Technology Corporation | 367.02M |
Sisram Medical News
- 2 months ago - Half Year 2025 Sisram Medical Ltd Earnings Call Transcript - GuruFocus
- 5 months ago - Sisram Medical reports 1H results - Seeking Alpha
- 1 year ago - Sirsram Medical announces NMPA approval for DAXXIFY® - Benzinga